Jürgen Floege1, Yumi Kubo2, Anna Floege3, Glenn M Chertow4, Patrick S Parfrey5. 1. Division of Nephrology, RWTH University of Aachen, Aachen, Germany; Juergen.floege@rwth-aachen.de. 2. Amgen Inc., Thousand Oaks, California; 3. Division of Nephrology, RWTH University of Aachen, Aachen, Germany; 4. Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California; and. 5. Department of Medicine, Memorial University, St. John's, Newfoundland, Canada.
Abstract
BACKGROUND AND OBJECTIVES:Uncontrolled secondary hyperparathyroidism (sHPT) in patients with ESRD is a risk factor for calcific uremic arteriolopathy (CUA; calciphylaxis). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Adverse event reports collected during the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events trial were used to determine the frequency of CUA in patients receiving hemodialysis who had moderate to severe sHPT, as well as the effects of cinacalcet versus placebo. CUA events were collected while patients were receiving the study drug. RESULTS: Among the 3861 trial patients who received at least one dose of the study drug, 18 patients randomly assigned toplacebo and six assigned to cinacalcet developed CUA (unadjusted relative hazard, 0.31; 95% confidence interval [95% CI], 0.13 to 0.79; P=0.014). Corresponding cumulative event rates (95% CI) at year 4 were 0.011% (0.006% to 0.018%) and 0.005% (0.002% to 0.010%). By multivariable analysis, other factors associated with CUA included female sex, higher body mass index, higher diastolic BP, and history of dyslipidemia or parathyroidectomy. Median (10%, 90% percentile) plasma parathyroid hormone concentrations proximal to the report of CUA were 796 (225, 2093) pg/ml and 410 (71, 4957) pg/ml in patients randomly assigned to placebo and cinacalcet, respectively. Active use of vitamin K antagonists was recorded in 11 of 24 patients with CUA, nine randomly assigned to placebo, and two to cinacalcet, in contrast to 5%-7% at any one time point in patients in whom CUA was not reported. CONCLUSION:Cinacalcet appeared to reduce the incidence of CUA in hemodialysis recipients who have moderate to severe sHPT.
RCT Entities:
BACKGROUND AND OBJECTIVES: Uncontrolled secondary hyperparathyroidism (sHPT) in patients with ESRD is a risk factor for calcific uremic arteriolopathy (CUA; calciphylaxis). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Adverse event reports collected during the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events trial were used to determine the frequency of CUA in patients receiving hemodialysis who had moderate to severe sHPT, as well as the effects of cinacalcet versus placebo. CUA events were collected while patients were receiving the study drug. RESULTS: Among the 3861 trial patients who received at least one dose of the study drug, 18 patients randomly assigned to placebo and six assigned to cinacalcet developed CUA (unadjusted relative hazard, 0.31; 95% confidence interval [95% CI], 0.13 to 0.79; P=0.014). Corresponding cumulative event rates (95% CI) at year 4 were 0.011% (0.006% to 0.018%) and 0.005% (0.002% to 0.010%). By multivariable analysis, other factors associated with CUA included female sex, higher body mass index, higher diastolic BP, and history of dyslipidemia or parathyroidectomy. Median (10%, 90% percentile) plasma parathyroid hormone concentrations proximal to the report of CUA were 796 (225, 2093) pg/ml and 410 (71, 4957) pg/ml in patients randomly assigned to placebo and cinacalcet, respectively. Active use of vitamin K antagonists was recorded in 11 of 24 patients with CUA, nine randomly assigned to placebo, and two to cinacalcet, in contrast to 5%-7% at any one time point in patients in whom CUA was not reported. CONCLUSION:Cinacalcet appeared to reduce the incidence of CUA in hemodialysis recipients who have moderate to severe sHPT.
Authors: Glenn M Chertow; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Jürgen Floege; William G Goodman; Charles A Herzog; Yumi Kubo; Gerard M London; Kenneth W Mahaffey; T Christian H Mix; Sharon M Moe; Marie-Louise Trotman; David C Wheeler; Patrick S Parfrey Journal: N Engl J Med Date: 2012-11-03 Impact factor: 91.245
Authors: Glenn M Chertow; Ricardo Correa-Rotter; Geoffrey A Block; Tilman B Drueke; Jürgen Floege; William G Goodman; Charles A Herzog; Yumi Kubo; Gerard M London; Kenneth W Mahaffey; Thomas-Christian Mix; Sharon M Moe; David C Wheeler; Patrick S Parfrey Journal: Nephrol Dial Transplant Date: 2012-04-23 Impact factor: 5.992
Authors: Rafael Kramann; Vincent M Brandenburg; Leon J Schurgers; Markus Ketteler; Saskia Westphal; Isabelle Leisten; Manfred Bovi; Willi Jahnen-Dechent; Ruth Knüchel; Jürgen Floege; Rebekka K Schneider Journal: Nephrol Dial Transplant Date: 2012-12-06 Impact factor: 5.992
Authors: Glenn M Chertow; Lara B Pupim; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drueke; Jürgen Floege; William G Goodman; Gerard M London; Kenneth W Mahaffey; Sharon M Moe; David C Wheeler; Moetaz Albizem; Kurt Olson; Preston Klassen; Patrick Parfrey Journal: Clin J Am Soc Nephrol Date: 2007-08-16 Impact factor: 8.237
Authors: T Coates; G S Kirkland; R B Dymock; B F Murphy; J K Brealey; T H Mathew; A P Disney Journal: Am J Kidney Dis Date: 1998-09 Impact factor: 8.860
Authors: Sagar U Nigwekar; Sophia Zhao; Julia Wenger; Jeffrey L Hymes; Franklin W Maddux; Ravi I Thadhani; Kevin E Chan Journal: J Am Soc Nephrol Date: 2016-04-14 Impact factor: 10.121
Authors: Vincent M Brandenburg; Smeeta Sinha; Jose-Vicente Torregrosa; Rekha Garg; Stephan Miller; Ana-Zeralda Canals; Daun Bahr; Pieter H Joubert; Carolina Salcedo; Kevin J Carroll; Alex Gold; Joan Perelló Journal: J Nephrol Date: 2019-08-10 Impact factor: 3.902
Authors: Patrick S Parfrey; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Jürgen Floege; Charles A Herzog; Gerard M London; Kenneth W Mahaffey; Sharon M Moe; David C Wheeler; Glenn M Chertow Journal: Clin J Am Soc Nephrol Date: 2015-11-27 Impact factor: 8.237